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Abstract
Background: Variations within the FOXA family have been studied for a putative contribution to the risk of type 2
diabetes (T2D), and recently the minor T-allele of FOXA2 rs1209523 was reported to associate with decreased fasting
plasma glucose levels in a study using a weighted false discovery rate control procedure to enhance the statistical
power of genome wide association studies in detecting associations between low-frequency variants and a given trait.
Thus, the primary aim of this study was to investigate whether the minor T-allele of rs1205923 in FOXA2 associated
with 1) decreased fasting plasma glucose and 2) a lower risk of developing T2D. Secondly, we investigated
whether rs1205923 in FOXA2 associated with other glucose-related phenotypes.
Methods: The variant was genotyped in Danish individuals from four different study populations using KASPar
®
PCR SNP genotyping system. We examined for associations of the FOXA2 genotype with fasting plasma glucose
and estimates of insulin release and insulin sensitivity following an oral glucose tolerance test in 6,162 Danish
individuals from the population-based Inter99 study while association with T2D risk was assessed in 10,196 Danish
individuals including four different study populations.
Results: The FOXA2 rs1209523 was not associated with fasting plasma glucose (effect size (b) = -0.03 mmol/l (95%
CI: -0.07; 0.01), p = 0.2) in glucose-tolerant individuals from the general Danish population. Furthermore, when
employing a case-control setting the variant showed no association with T2D (odds ratio (OR) = 0.82 (95%CI: 0.62-
1.07), p = 0.1) among Danish individuals. However, when we performed the analysis in a subset of 6,022 non-obese
individuals (BMI < 30 kg/m
2) an association with T2D was observed (OR = 0.68 (95%CI: 0.49-0.94), p = 0.02). Also,
several indices of insulin release and b-cell function were associated with the minor T-allele of FOXA2 rs1209523 in
non-obese individuals.
Conclusions: We failed to replicate association of the minor T-allele of FOXA2 rs1209523 with fasting plasma
glucose in a population based sample of glucose tolerant individuals. More extensive studies are needed in order
to fully elucidate the potential role of FOXA2 in glucose homeostasis.
Background
Type 2 diabetes (T2D) is a common and complex dis-
ease characterized by a state of hyperglycemia resulting
from defects in insulin action combined with dysfunc-
tion of the pancreatic b-cell. Still, the underlying genetic
factors affecting the susceptibility for developing T2D
and associated complications remain poorly elucidated.
The Forkhead box A2 gene (FOXA2) encodes an
upstream activator of the b-cell transcription factor net-
work and variation in this gene is hypothesized to play a
role in T2D pathogenesis. Studies have shown that mice
lacking Foxa2 in pancreatic b-cells are severely hypogly-
caemic and show hypersecretion of insulin in response
to both glucose and amino acid stimuli, suggesting that
Foxa2 has to be present in pancreatic b-cells in order to
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any medium, provided the original work is properly cited.sustain appropriate circulating levels of insulin as well as
for maintaining glucose homeostasis [1].
In humans, variations within the FOXA family have
been studied for a putative contribution to the risk of
developing T2D. A study by Zhu et al. found no statisti-
cally significant association between FOXA2 variants
and T2D in a Japanese study sample (n = 208) [2]. In a
study by Navas and colleagues, all three FOXA genes
were sequenced in a sample of 96 T2D patients with
mixed ancestry; however, no mutations within the cod-
ing regions of any of the three genes were found, sug-
gesting that mutations within FOXA genes are not a
common cause of T2D [3]. A more recent study, how-
ever, reported an association between the FOXA2
rs1055080 and a reduced risk of T2D in a North Indian
study sample (n = 1,656) [4]. In line with this, Xing et
al. identified FOXA2 rs1209523 (in high linkage disequi-
librium (LD) with rs1055080 (CEU; r
2 = 0.82)) employ-
ing a weighted false discovery rate control procedure to
enhance the statistical power of genome wide associa-
tion studies (GWAS) in detecting associations between
low-frequency variants and fasting plasma glucose levels
[5]. This low-frequency variant (rs1209523; minor T-
allele frequency = 4.3%) was shown to be associated
with lowered levels of fasting plasma glucose in both
European Americans (n = 7,428, p =1 . 3×1 0
-3)a n d
African Americans (n =2 , 0 2 9 ,p =6 . 7×1 0
-3)[ 5 ] .A
meta-analysis of the five included studies (n = 11,734)
generated an estimated effect size of -1.31 mg/dl fasting
plasma glucose level per minor allele (pall samples =2 . 2×
10
-11) [5].
Therefore, the primary aim of the current study was
to investigate whether the minor T-allele of rs1205923
in FOXA2 associated with 1) decreased fasting plasma
glucose among 6,162 Danish individuals from the popu-
lation-based Inter99 study, and 2) a lower risk of devel-
oping T2D in 10,196 Danish individuals including four
different study populations. Secondly, we investigated
whether rs1205923 in FOXA2 associated with other
traits related to glucose metabolism that could explain
the previously found associations with T2D-related
metabolic traits.
Methods
The study was conducted in accordance with the Hel-
sinki Declaration and approved by the Ethical Commit-
tees of Copenhagen and Aarhus.
Study participants
Participants were of Danish nationality and prior to par-
ticipation, a written informed consent was obtained
from all individuals. Participants examined in the pre-
sent study were from four different study populations:
1) The Inter99 study is a population-based randomized
non-pharmacological intervention study for the preven-
tion of ischaemic heart disease from the Research Cen-
tre for Prevention and Health in Glostrup, Denmark
(ClinicalTrials.gov NTC00289237) [6]. A total of 6,162
participants with available genotypes for rs1209523 were
classified as having normal glucose tolerance (NGT) (n
= 4,567), impaired fasting glycemia (n=508), impaired
glucose tolerance (n = 707), screen-detected T2D (n =
256), or previously diagnosed T2D (n = 124); 2) T2D
patients recruited at Steno Diabetes Center (SDC) (n =
1,695); 3) A random sample of middle-aged glucose-tol-
erant participants examined at SDC (n =7 3 0 )a n d4 )
T2D patients from the population-based, high-risk Addi-
tion Denmark screening and intervention study cohort
(n = 1,609) (Anglo-Danish-Dutch Study of Intensive
Treatment in People with Screen-Detected Diabetes in
Primary Care) (ClinicalTrials.gov ID-no: NCT00237548).
A standard 75 g oral glucose tolerance test (OGTT) was
performed in participants from study group 1 and 3.
T2D was diagnosed according to World Health Organi-
zation 1999 criteria.
Analyses of quantitative diabetes-related traits were
performed in glucose-tolerant individuals (n =4 , 5 6 7 ) ,a s
well as in non-obese (BMI < 30 kg/m
2) individuals (n =
4,022) from study population 1. All T2D patients and
glucose-tolerant individuals were included in the case-
control study of T2D (n = 10,196). In the T2D case-con-
trol study of non-obese individuals, study participants
w i t haB M Ia b o v e3 0w e r ee x c l u d e df o rb o t hT 2 Di n d i -
viduals and glucose-tolerant controls.
Genotyping
The rs1209523 of FOXA2 was genotyped using KASPar
®
SNP Genotyping system (KBioscience, Hoddesdon, UK).
T h es u c c e s sr a t ew a s9 7 . 3 %w i t ha0 . 0 %e r r o rr a t ee s t i -
mated from re-genotyping of 972 replicate samples. The
genotype distribution obeyed Hardy-Weinberg equili-
brium in all study populations (p > 0.14).
Biochemical and anthropometric measures
Height and weight were measured in light indoor cloth-
ing and without shoes. Hip circumference was measured
at its maximum, and waist circumference was measured
in the upright position midway between the iliac crest
and the lower costal margin [6] BMI was calculated as
weight (kg)/height
2 (m
2). Blood samples were drawn
after a 12 h overnight fast. A glucose oxidase method
was used to analyze plasma glucose (Granutest; Merck,
Darmstadt, Germany). Serum insulin (excluding des-
31,32 and intact proinsulin) was measured using the
Autodelfia insulin kit (Perkin-Elmer/Wallac, Turku, Fin-
land). Serum C-peptide concentrations were measured
by a time-resolved fluoroimmunoassay (Auto-DELFIA
C-peptide kit; Perkin-Elmer/Wallac, Turku, Finland).
Homeostasis model assessment of insulin resistance
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(mmol/l) × fasting serum insulin (pmol/l))/22.5, and
homeostasis model assessment of b-cell function
(HOMA-B) was calculated as: (20 × fasting serum insu-
lin (pmol/l))/(fasting plasma glucose (mmol/l) - 3.5) [7].
Information on sex, BMI, plasma glucose levels, and
serum insulin levels to time points 0, 30, and 120 min
during an OGTT is used to calculate the BIGTT-acute
insulin response (BIGTT-AIR) as well as the BIGTT-
insulin sensitivity index (BIGTT-Si). These indices
highly correlate with those obtained during an intrave-
nous glucose tolerance test. The calculations were per-
formed as previously described [8]. Insulinogenic index
was calculated as: (serum insulin at 30 min (pmol/l) -
fasting serum insulin (pmol/l))/plasma glucose at 30
min (mmol/l). Disposition index was calculated as insu-
linogenic index/HOMA-IR, and Matsuda whole body
insulin sensitivity index (ISIMatsuda) was calculated as
(10,000/√ (fasting plasma glucose × fasting serum insu-
lin) × (mean plasma glucose × mean serum insulin dur-
ing OGTT)) [9]. The trapezoidal method was used to
estimate the area under the curve (AUC) for plasma glu-
cose, serum insulin and serum C-peptide, and the AUC
for insulin/AUC for glucose ratio was calculated as
AUC for insulin/AUC for glucose.
Statistical analysis
All statistical analyses were performed using R statistical
software version 2.12.1 (available at http://www.rproject.
org). A general linear model was applied to test quanti-
tative traits in relation to genotype, using an additive
genetic model and adjusting for age, sex, and BMI
where appropriate. Prior to analyses, non-normally dis-
tributed data (measures of serum insulin, serum C-pep-
tide levels, insulinogenic index, HOMA-IR, ISIMatsuda,
AUC for insulin/AUC for glucose ratio, and BIGTT-
AIR) were logarithmically transformed. Logistic regres-
sion was used to compare allele frequencies in the case-
control analysis, and the analysis was adjusted for age,
sex, and BMI. A p-value of less than 0.05 was consid-
ered statistically significant. The statistical power for
detecting an effect on fasting plasma glucose of -
0.07205 mmol/l per allele corresponding to -1.31 mg/dl
found by Xing and colleagues [5] was estimated using
1,000 simulations and a significance threshold of 0.05.
Based on the allele frequency of the variant and the
sample size of 4,368 non-diabetic successfully genotyped
individuals, we estimated a statistical power of 93% to
detect an association. For comparison, the statistical
power to detect an effect on fasting plasma glucose of
0.06, 0.05, 0.04, or 0.03 mmol/l per allele were 79%,
66%, 46%, or 30%, respectively.
The statistical power calculation for the case-control
analysis was done using CaTS, power calculations for
large genetic association studies http://www.sph.umich.
edu/csg/abecasis/cats/, and the statistical power to
detect an OR of 0.85, 0.90, or 0.95 for rs1209523 of
FOXA2 was estimated to be 50%, 26%, or 10%, respec-
tively (significance level: p < 0.05, minor allele frequency
( M A F )=4 % ,e s t i m a t e dT 2 Dp r e v a l e n c ei nt h eb a c k -
ground population = 0.08).
Functional prediction
FASTSNP (Function Analysis and Selection Tool for
Single Nucleotide Polymorphisms; http://fastsnp.ibms.
sinica.edu.tw) was used to predict the function of
rs1209523 in FOXA2.
External data
Data on glycemic traits have been contributed by
MAGIC investigators and have been downloaded from
http://www.magicinvestigators.org[10]. Data on T2D
were available through the DIAGRAM meta-analysis
[11].
Results and discussion
Association with fasting plasma glucose
We analyzed the FOXA2 rs1209523 minor T-allele
which is located in the promoter region of the gene and
is predicted by FASTSNP to have a very low to medium
functional effect on FOXA2 function, for association
with fasting plasma glucose in glucose-tolerant indivi-
duals from the Inter99 study population. No statistically
significant association was found (effect size (b)=- 0 . 0 3
mmol/l (95%CI: -0.07; 0.01), p = 0.2) (Table 1). Consid-
ering the high statistical power to detect an association
in the present study, this suggests that the variant may
only have a minor effect on fasting plasma glucose levels
among Danish individuals. Similarly, no associations
were found between rs1209523 and plasma glucose
levels after 30-min and 120-min during an OGTT
(Table 1).
The weighted false discovery rate control procedure
applied by Xing and colleagues to enhance the statistical
power of detecting associations with low frequency var-
iants was shown to boost the p- v a l u e so fv a r i a n t sw i t h
even small effect sizes to genome-wide significance [5].
As mentioned by the authors, the weighted false discov-
ery rate control procedure is a prototype and its proper-
ties in GWAS should be further investigated. A large
meta-analysis (n = 46,263) of European-ancestry-based
GWAS on fasting glucose levels failed to identify a gen-
ome-wide significant association with FOXA2 (b =
-0.028 mmol/l, p = 0.00394) [10]. This may, as Xing et
al. suggest, be attributed to the low MAF of the variant
which makes it less likely to detect an association com-
pared to more frequent variants with a similar effect
size. However, it is more likely that the effect size
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example of “winners curse”, and a lower effect size for
fasting plasma glucose would cause a considerably
decreased power to detect associations in this study.
Larger studies in study populations of different origin
are needed to evaluate an effect of FOXA2 rs1209523 on
fasting plasma glucose levels.
Association with T2D
We investigated, in a case-control setting (ncases(CC/CT/
TT): 3340/166/1 vs. ncontrols(CC/CT/TT): 4567/300/8),
whether rs1209523 of FOXA2 associated with a
decreased risk of developing T2D as indicated by the
findings by Xing et al. [5]. No statistically significant
association with T2D was found (odds ratio (OR) = 0.82
(95%CI: 0.62-1.07), p = 0.1) (Table 2). The OR, however,
indicates that the minor T-allele of rs1209523 may exert
a protective effect on T2D risk, although not statistically
significant. Yet, the observed effect on T2D is not com-
parable to the one observed in the DIAGRAM meta-
analysis (OR = 1.12 (0.94-1.34), p = 0.2) [11]. Consider-
ing the relatively low statistical power in our study, the
indication of a protective effect of the variant on T2D is
to be considered a chance-finding.
Table 1 Anthropometric and metabolic characteristics of successfully genotyped glucose-tolerant Danish individuals
from the Inter99 study according to rs1209523 FOXA2 genotype
rs1209523 CC CT TT b [95%CI] padd
n (men/women) 4,091(1,880/2,211) 269(133/136) 8(6/2)
Age (years)
¥ 45.2 ± 7.9 44.8 ± 7.3 45.7 ± 7.2
BMI
¥ 25.5 ± 4.1 25.5 ± 3.6 25.8 ± 2.4 -0.02 [-0.49; 0.45] 0.9
Plasma glucose (mmol/l)
Fasting
¥ 5.3 ± 0.4 5.3 ± 0.4 5.6 ± 0.3 -0.03 [-0.07; 0.01] 0.2
30-min during an OGTT
¥ 8.2 ± 1.5 8.2 ± 1.5 8.9 ± 1.1 0.04 [-0.12; 0.21] 0.6
120-min during an OGTT
¥ 5.5 ± 1.1 5.5 ± 1.1 5.3 ± 1.2 -0.02 [-0.14;0.11] 0.8
Incremental AUC
¥ 181 ± 101 186 ± 98 185 ± 73 5.36 [-6.26;
16.98]
0.4
Serum insulin (pmol/l)
Fasting 31 (22-45) 34 (23-49) 42 (30-50) 5.0% [-0.9; 10.8] 0.1
30-min during an OGTT 242 (175-344) 248 (188-346) 314 (232-425) 7.9% [2.1; 13.7] 0.008
120-min during an OGTT 136 (86-209) 137 (94-216) 212 (120-240) 9.3% [1.4; 17.3] 0.02
Incremental AUC 17,720 (12,540-25,020) 17,300 (13,680-25,800) 18,360 (14,250-28,120) 7.9% [1.6; 14.2] 0.01
Serum C-peptide (pmol/l)
Fasting 493 (391-631) 520 (407-663) 602 (564-726) 3.8% [0.2; 7.5] 0.04
30-min during an OGTT 1,870 (1,470-2,360) 1,950 (1,580-2,412) 2,505 (1,685-2,738) 4.3% [0.4; 8.2] 0.03
120-min during an OGTT 1,960 (1,480-2,490) 1,990 (1,580-2,520) 2,485 (1,975-2,968) 5.0% [0.6; 9.3] 0.03
Incremental AUC 147,800 (117,200-
183,200)
150,700 (122,700-
185,400)
176,500 (150,000-
199,400)
4.6% [0.7; 8.4] 0.02
Derived indices
b-cell function
Insulinogenic index 25.8 (17.9-37.6) 26.0 (19.6-39.0) 34.3 (19.7-42.4) 7.0% [0.5; 13.5] 0.03
BIGTT-AIR 1,672 (1,348-2,099) 1,710 (1,387-2,191) 1,455 (1,238-2,500) 3.5% [-1.1; 8.1] 0.1
HOMA-B 353 (248-508) 380 (267-560) 401 (310-488) 6.9% [0.9; 12.9] 0.02
AUCinsulin/AUCglucose 27.3 (20.2-37.4) 27.8 (21.1-39.7) 29.2 (23.2-40.8) 6.5% [1.2; 11.9] 0.02
Insulin sensitivity
HOMA-IR 7.4 (5.2-10.9) 7.9 (5.4-11.8) 10.5 (7.8-11.8) 4.4% [-1.6; 10.4] 0.2
BIGTT-Si
¥ 10.4 ± 3.7 10.1 ± 3.7 8.6 ± 3.3 -0.33 [-0.78; 0.12] 0.2
ISIMatsuda 25.9 (18.2-35.6) 24.4 (16.8-34.5) 19.2 (15.0-26.5) -5.8% [-11.2; -0.4] 0.03
b-cell function corrected for insulin
sensitivity
Disposition index 3.5 (2.3-5.2) 3.7 (2.4-5.4) 3.9 (3.0-4.2) 2.6% [-4.9; 10.1] 0.5
Data are unadjusted means ± SD
¥ or medians (interquartile range). Values of serum insulin, serum c-peptide, and insulin-derived indices were logarithmically
transformed prior to statistical analyses, and their effect sizes are presented as the increase/decrease in percent. Effect sizes (b) and p-values shown are for an
additive genetic model and are adjusted for age, sex, and BMI where appropriate. CI, confidence interval; add, additive; AUC, area under the curve.
Banasik et al. BMC Medical Genetics 2012, 13:10
http://www.biomedcentral.com/1471-2350/13/10
Page 4 of 7On the contrary, our finding corresponded well to the
findings by Tabassum and colleagues where a protective
effect on T2D risk among normal-weight North Indians
(n = 566) was observed for FOXA2 rs1055080 (OR =
0.59 (0.40-0.88), p = 0.011) [4]. Due to the strong LD
between rs1055080 and rs1209523 (CEU; r
2 =0 . 8 2 )t h e
association signals are likely to originate from the same
causal variant. Therefore, we investigated whether
rs1209523 of FOXA2 associated with a decreased risk of
developing T2D among non-obese (BMI < 30 kg/m
2)
Danish individuals (ncases(BMI < 30)(CC/CT/TT): 1653/77/
0v s .ncontrols(BMI < 30)(CC/CT/TT): 4012/272/8) (Table
2). Here we found that rs1209523 of FOXA2 associated
with a statistically significant decrease in the risk of
developing T2D (OR = 0.68 (95%CI: 0.49-0.94), p =
0.02) (Table 2). Whether this is a true finding needs
further investigation in other independent study
populations.
Associations with glucose-related phenotypes
When FOXA2 rs1209523 was analyzed for associations
with glucose-related phenotypes, the T-allele signifi-
cantly associated with increased serum insulin levels
after 30-min (b = 7.9% (2.1; 13.7), p = 0.008) and 120-
min (b = 9.3% (1.4; 17.3), p = 0.02) during an OGTT
(Table 1). Furthermore, the rs1209523 T-allele asso-
ciated with an increased incremental AUC for insulin (b
= 7.9% (1.6; 14.2), p = 0.01) during the OGTT (Table 1).
The associations were underpinned by significant asso-
ciations for serum C-peptide levels during the OGTT
(Table 1). In line with these results, several indices of
insulin release and b-cell function showed significantly
increased levels for the FOXA2 rs1209523 minor T-allele
(Table 1). The indication of a general effect on b-cell
function is supported by the findings reported by the
MAGIC investigators where the T-allele of rs1209523 in
FOXA2 significantly associated with an increased
HOMA-B (b = 0.037 (standard error: 0.0093), p =6 . 5 9 5
×1 0
-5).
To test whether these associations were independent
of BMI, we conducted the analysis without adjusting for
BMI, and the associations remained significant (data not
shown). Likewise, stratifying the analysis according to
BMI using a cut-off of 30 kg/m
2 showed that the signifi-
cant associations were driven by the non-obese (BMI <
30 kg/m
2) individuals (Table 3). However, these data
should be interpreted with caution since no obese indi-
viduals were homozygous for the minor T-allele of
rs1209523. Indices of insulin sensitivity (HOMA-IR and
BIGTT-Si)s h o w e dn oe v i d e n c eo fa s s o c i a t i o n sw i t h
FOXA2 rs1209523 among glucose-tolerant individuals.
None of the identified associations in this study would
remain significant after Bonferroni corrections.
Altogether, our findings may suggest that the
improved b-cell function in carriers of the rs1209523
minor T-allele may play a role in the observed lowered
fasting plasma glucose levels. A study by Gao et al.
showed that inducible ablation of both Foxa1 and Foxa2
in mature mouse b-cells lead to impaired glucose home-
ostasis with impaired insulin secretion, suggesting that
these transcription factors play a crucial role in the
development and maintenance of b-cell specific secre-
tory and metabolic pathways [12]. Interestingly, Gao et
al. also showed that the gene encoding hydroxyacyl-
coenzyme A dehydrogenase (Hadh) is down regulated
2.4-fold in Foxa2 deficient b-cells and 5.4-fold in b-cells
lacking both Foxa1 and Foxa2 [12]. Decreased expres-
sion of the gene encoding a related mitochondrial fatty
acid oxidation enzyme, the short-chain specific acyl-
CoA dehydrogenase (ACADS) has been hypothesized to
impair insulin secretion [13], and a study by our group
has previously shown that the minor C-allele of
rs2014355 in ACADS associated with reduced measures
of glucose-stimulated insulin release [14]. Thus, altered
Table 2 Genotype distribution and allele frequency for FOXA2 rs1209523 among patients with T2D and glucose-
tolerant control individuals
n (men/women) CC (%) CT (%) TT (%) MAF
(95% CI)
OR (95% CI) Padd
All individuals
NGT 4,875 (2,256/2,619) 4,567 (93.7) 300 (6.2) 8 (0.2) 3.2
(2.9-3.6)
0.82 (0.62-1.07) 0.1
T2D 3,507 (2,084/1,423) 3,340 (95.2) 166 (4.7) 1 (0.1) 2.4
(2.1-2.8)
Non-obese individuals (BMI < 30 kg/m
2)
NGT 4,292 (1,999/2,293) 4,012 (93.5) 272 (6.3) 8 (0.2) 3.4
(3.0-3.8)
0.68 (0.49-0.94) 0.02
T2D 1,730 (1,096/634) 1,653 (95.5) 77 (4.5) 0 (0) 2.2
(1.8-2.8)
Number of individuals divided into genotype groups (% in each group), and frequencies of the minor allele (MAF) in percentages. Logistic regression was used to
compare allele frequencies (Padd). The odds ratios (OR) and the 95% confidence interval (CI) are given for comparison of allele frequency. NGT: Glucose-tolerant
individuals, T2D: type 2 diabetic patients.
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potentially in combination with the regulation of genes
expressed in the same molecular pathway.
Conclusions
The FOXA2 rs1209523 was not significantly associated
with fasting plasma glucose in glucose-tolerant indivi-
duals from the general Danish population of middle-
aged people. Furthermore, when employing a case-con-
trol setting the T-allele was not found to be significantly
associated with the risk of developing T2D. However,
when we performed the analysis exclusively in non-
obese individuals (BMI < 30 kg/m
2), a significant
association with T2D was observed. Also, several indices
of insulin release and b-cell function showed signifi-
cantly increased levels for the FOXA2 rs1209523 minor
T-allele in the non-obese study population. More exten-
sive studies are needed in order to fully elucidate the
potential contribution of variation in FOXA2 to glucose
homeostasis.
List of abbreviations
AUC: Area under the curve; BIGTT-AIR: BIGTT-acute insulin response; BIGTT-Si:
BIGTT-insulin sensitivity index; FOXA: Forkhead box A; GWAS: Genome-wide
association study; HOMA-B: Homeostasis model assessment of β-cell
function; HOMA-IR: Homeostasis model assessment of insulin resistance; IR:
Insulin resistance; ISIMatsuda: Matsuda whole body insulin sensitivity index; LD:
Table 3 Anthropometric and metabolic characteristics of successfully genotyped non-obese (BMI < 30 kg/m
2) glucose-
tolerant Danish individuals from the Inter99 study according to rs1209523 FOXA2 genotype
rs1209523 CC CT TT b [95%CI] padd
n (men/women) 3,597(1,663/1,934) 244(121/123) 8(6/2)
Age (years)
¥ 45.1 ± 7.9 44.7 ± 7.2 45.7 ± 7.2
BMI
¥ 24.1 ± 7.9 24.7 ± 2.8 25.8 ± 2.4 0.32 [-0.004; 0.65] 0.05
Plasma glucose (mmol/l)
Fasting
¥ 5.3 ± 0.4 5.2 ± 0.4 5.6 ± 0.3 -0.03 [-0.07; 0.02] 0.3
30-min during an OGTT
¥ 8.1 ± 1.5 8.2 ± 1.4 8.9 ± 1.1 0.05 [-0.13; 0.22] 0.6
120-min during an OGTT
¥ 5.4 ± 1.1 5.4 ± 1.1 5.3 ± 1.2 -0.01 [-0.15;0.12] 0.8
Incremental AUC
¥ 176 ± 102 182 ± 96 185 ± 73 5.64 [-6.64; 17.92] 0.4
Serum insulin (pmol/l)
Fasting 29 (21-41) 32 (22-44) 42 (30-50) 6.5% [0.02; 13.0] 0.2
30-min during an OGTT 229 (168-321) 244 (186-327) 314 (232-425) 9.2% [2.9; 15.6] 0.01
120-min during an OGTT 131 (83-194) 135 (92-198) 212 (120-240) 10.9% [2.5; 19.4] 0.03
Incremental AUC 16,880 (12,140-23,300) 16,500 (13,240-23,430) 18,360 (14,250-28,120) 9.1% [2.4; 15.9] 0.02
Serum C-peptide (pmol/l)
Fasting 473 (381-592) 495 (398-604) 602 (564-726) 4.7% [0.6; 8.8] 0.09
30-min during an OGTT 1,820 (1,440-2,280) 1,920 (1,525-2,315) 2,505 (1,685-2,738) 5.2% [1.0; 9.4] 0.05
120-min during an OGTT 1,900 (1,450-2,400) 1,950 (1,548-2,420) 2,485 (1,975-2,968) 5.8% [1.2; 10.4] 0.03
Incremental AUC 144,200 (115,100-
177,800)
149,000 (122,000-
182,000)
176,500 (150,000-
199,400)
5.4% [1.3; 9.5] 0.03
Derived indices
b-cell function
Insulinogenic index 24.7 (17.3-35.7) 24.9 (18.5-36.9) 34.3 (19.7-42.4) 8.2% [1.2; 15.1] 0.04
BIGTT-AIR 1,596 (1,311-1,973) 1,665 (1,361-2,060) 1,455 (1,238-2,500) 5.7% [1.4; 10.0] 0.01
HOMA-B 337 (240-399) 367 (263-515) 401 (310-488) 6.7% [0.4; 13.1] 0.04
AUCinsulin/AUCglucose 26.0 (19.6-34.9) 27.0 (20.4-37.9) 29.2 (23.2-40.8) 7.7% [2.0; 13.5] 0.01
Insulin sensitivity
HOMA-IR 7.0 (4.9-9.8) 7.5 (5.0-10.6) 10.5 (7.8-11.8) 5.9% [-0.8; 12.7] 0.2
BIGTT-Si
¥ 11.0 ± 3.3 10.6 ± 3.5 8.6 ± 3.3 -0.53 [-0.95; 0.10] 0.02
ISIMatsuda 27.4 (19.9-36.9) 26.6 (18.1-35.7) 19.2 (15.0-26.5) -7.2% [-13.5; -1.1] 0.02
b-cell function corrected for insulin sensitivity
Disposition index 3.6 (2.4-5.3) 3.9 (2.4-5.6) 3.9 (3.0-4.2) 2.5% [-5.4; 10.5] 0.5
Data are unadjusted means ± SD
¥ or medians (interquartile range). Values of serum insulin, serum c-peptide, and insulin-derived indices were logarithmically
transformed prior to statistical analyses, and their effect sizes are presented as the increase/decrease in percent. Effect sizes (b) and p-values shown are for an
additive genetic model and are adjusted for age and sex. CI, confidence interval; add, additive; AUC, area under the curve.
Banasik et al. BMC Medical Genetics 2012, 13:10
http://www.biomedcentral.com/1471-2350/13/10
Page 6 of 7Linkage disequilibrium; OGTT: Oral glucose tolerance test; SDC: Steno
Diabetes Center; SNP: Single nucleotide polymorphism; T2D: Type 2
diabetes.
Acknowledgements
The authors wish to thank A. Forman, T. Lorentzen and M. Stendal for
technical assistance, G. Lademann for secretarial support, A. Nielsen and P.
Sandbeck for data management and M. Kristensen for grant management.
This work received support from the Lundbeck Foundation Centre for
Applied Medical Genomics in Personalized Disease Prediction, Prevention
and Care (LuCAMP, http://www.lucamp.org). The Inter99 was initiated by
Torben Jørgensen (PI), Knut Borch-Johnsen (co-PI), Hans Ibsen and Troels F.
Thomsen. The steering committee comprises the former two and Charlotta
Pisinger.
Author details
1The Novo Nordisk Foundation Center for Basic Metabolic Research, Section
of Metabolic Genetics, Faculty of Health Sciences, University of Copenhagen,
Copenhagen, Denmark.
2Department of General Practice, University of
Aarhus, Aarhus, Denmark.
3Faculty of Health Sciences, University of
Copenhagen, Copenhagen, Denmark.
4Research Centre for Prevention and
Health, Glostrup University Hospital, Glostrup, Denmark.
5Steno Diabetes
Center, Gentofte, Denmark.
6Faculty of Health Sciences, University of Aarhus,
Aarhus, Denmark.
7Hagedorn Research Institute, Gentofte, Denmark.
8Faculty
of Health Sciences, University of Southern Denmark, Odense, Denmark.
Authors’ contributions
The concept and idea regarding the epidemiological studies underlying the
study populations was conceived by TJ, AS, TL, OP, and TH. The collection of
study subjects was planned and performed by TJ, AS, TL, OP, and TH. The
original hypothesis regarding the study was conceived by TH and approved
by OP. Detailed planning of analyses and study design was performed by
KB, MH and TS and approved by OP and TH. KB, MH, EA, DW, OP, and TH
contributed to the establishment of study population databases specific for
this study. Statistical analyses in association studies were performed by KB,
MH, TS and EA. The first manuscript was written by KB and MH with equal
contribution and the final draft was finalized by KB, MH, OP and TH. All
authors revised the manuscript and contributed to the discussion. The final
manuscript was read and approved by all authors.
Competing interests
K. Banasik, T. Hansen and O. Pedersen hold employee shares in Novo
Nordisk A/S. All other authors declare that there is no competing interest
associated with this manuscript.
Received: 28 July 2011 Accepted: 12 February 2012
Published: 12 February 2012
References
1. Sund NJ, Vatamaniuk MZ, Casey M, Ang SL, Magnuson MA, Stoffers DA,
Matschinsky FM, Kaestner KH: Tissue-specific deletion of Foxa2 in
pancreatic beta cells results in hyperinsulinemic hypoglycemia. Genes
Dev 2001, 15(13):1706-1715.
2. Zhu Q, Yamagata K, Yu L, Tomura H, Yamada S, Yang Q, Yoshiuchi I,
Sumi S, Miyagawa J, Takeda J, Hanafusa T, Matsuzawa Y: Identification of
missense mutations in the hepatocyte nuclear factor-3beta gene in
Japanese subjects with late-onset Type II diabetes mellitus. Diabetologia
2000, 43(9):1197-1200.
3. Navas MA, Vaisse C, Boger S, Heimesaat M, Kollee LA, Stoffel M: The human
HNF-3 genes: cloning, partial sequence and mutation screening in
patients with impaired glucose homeostasis. Hum Hered 2000,
50(6):370-381.
4. Tabassum R, Chavali S, Dwivedi OP, Tandon N, Bharadwaj D: Genetic
variants of FOXA2: risk of type 2 diabetes and effect on metabolic traits
in North Indians. Journal of Human Genetics 2008, 53(11-12):957-965.
5. Xing C, Cohen JC, Boerwinkle E: A weighted false discovery rate control
procedure reveals alleles at FOXA2 that influence fasting glucose levels.
Am J Hum Genet 2010, 86(3):440-446.
6. Jørgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C:
A randomized non-pharmacological intervention study for prevention of
ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev
Rehabil 2003, 10(5):377-386.
7. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC:
Homeostasis model assessment: insulin resistance and beta-cell function
from fasting plasma glucose and insulin concentrations in man.
Diabetologia 1985, 28(7):412-419.
8. Hansen T, Drivsholm T, Urhammer SA, Palacios RT, Volund A, Borch-
Johnsen K, Pedersen O: The BIGTT test: a novel test for simultaneous
measurement of pancreatic beta-cell function, insulin sensitivity, and
glucose tolerance. Diabetes Care 2007, 30(2):257-262.
9. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral
glucose tolerance testing: comparison with the euglycemic insulin
clamp. Diabetes Care 1999, 22(9):1462-1470.
10. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU,
Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL, Lindgren CM, Magi R,
Morris AP, Randall J, Johnson T, Elliott P, Rybin D, Thorleifsson G,
Steinthorsdottir V, Henneman P, Grallert H, Dehghan A, Hottenga JJ,
Franklin CS, Navarro P, Song K, Goel A, Perry JR, Egan JM, Lajunen T, et al:
New genetic loci implicated in fasting glucose homeostasis and their
impact on type 2 diabetes risk. Nat Genet 2010, 42(2):105-116.
11. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, de Bakker PI,
Abecasis GR, Almgren P, Andersen G, Ardlie K, Bostrom KB, Bergman RN,
Bonnycastle LL, Borch-Johnsen K, Burtt NP, Chen H, Chines PS, Daly MJ,
Deodhar P, Ding CJ, Doney AS, Duren WL, Elliott KS, Erdos MR, Frayling TM,
Freathy RM, Gianniny L, Grallert H, Grarup N, et al: Meta-analysis of
genome-wide association data and large-scale replication identifies
additional susceptibility loci for type 2 diabetes. Nat Genet 2008,
40(5):638-645.
12. Gao N, Le Lay J, Qin W, Doliba N, Schug J, Fox AJ, Smirnova O,
Matschinsky FM, Kaestner KH: Foxa1 and Foxa2 maintain the metabolic
and secretory features of the mature beta-cell. Mol Endocrinol 2010,
24(8):1594-1604.
13. Clayton PT, Eaton S, ynsley-Green A, Edginton M, Hussain K, Krywawych S,
Datta V, Malingre HE, Berger R, van dBI: Hyperinsulinism in short-chain L-
3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of
beta-oxidation in insulin secretion. JClinInvest 2001, 108(3):457-465.
14. Hornbak M, Banasik K, Justesen JM, Krarup NT, Sandholt CH, Andersson A,
Sandbaek A, Lauritzen T, Pisinger C, Witte DR, Sorensen TA, Pedersen O,
Hansen T: The minor C-allele of rs2014355 in ACADS is associated with
reduced insulin release following an oral glucose load. BMC Med Genet
2011, 12:4.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/13/10/prepub
doi:10.1186/1471-2350-13-10
Cite this article as: Banasik et al.: The effect of FOXA2 rs1209523 on
glucose-related phenotypes and risk of type 2 diabetes in Danish
individuals. BMC Medical Genetics 2012 13:10.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Banasik et al. BMC Medical Genetics 2012, 13:10
http://www.biomedcentral.com/1471-2350/13/10
Page 7 of 7